Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (5): 7-15.doi: 10.6040/j.issn.1671-7554.0.2024.0137

• Precision medicine in chronic airway diseases—Expert Overview • Previous Articles    

Clinical research hotspots of chronic obstructive pulmonary disease in recent years

WANG Fengyan1, LIANG Zhenyu1, LI Xueping1, CHEN Rongchang1,2   

  1. 1. Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong, China;
    2. Department of Respiratory and Critical Care Medicine, Institute of Shenzhen Respiratory Diseases, Shenzhen Peoples Hospital, Shenzhen 518020, Guangdong, China
  • Published:2024-05-29

PDF (PC)

67

Abstract: Chronic obstructive pulmonary disease(COPD)is the most common chronic respiratory disease, and has attracted much attention because of its disabling and fatal nature. Many important advances in clinical research have been made in recent years. The development of early diagnostic and screening tools, as well as multidimensional phenotyping based on lung function trajectories, quantitative imaging assessments and gene signature, have informed individualized treatment of COPD. Multi-omics studies have made important breakthroughs in exploring biomarkers of COPD, contributing to an in-depth understanding of the pathogenesis and progression of the disease. The comparisons of inhaled drug regimens and the efficacy of monoclonal antibodies targeting type 2 inflammation are also advancing, with a view to providing more individualized treatments for patients with COPD by targeting the pathogenesis of the disease.

Key words: Pulmonary disease, chronic obstructive, Clinical research hotspots, Phenotype, Individualized treatment

CLC Number: 

  • R574
[1] Li XC, Cao XP, Guo MZ, et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017[J]. BMJ, 2020, 368: m234. doi:10.1136/bmj.m234.
[2] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseas(2011 report)[EB/OL].(2011-12-01)[2024-01-30]. https://goldcopd.org/.
[3] Divo MJ, Liu CJ, Polverino F, et al. From pre-COPD to COPD: a simple, low cost and easy to IMplement(SLIM)risk calculator[J]. Eur Respir J, 2023, 62(3): 2300806. doi:10.1183/13993003.00806-2023.
[4] Young AL, Bragman FJS, Rangelov B, et al. Disease progression modeling in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2020, 201(3): 294-302.
[5] Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts[J]. Lancet Respir Med, 2020, 8(7): 696-708.
[6] Cosentino J, Behsaz B, Alipanahi B, et al. Inference of chronic obstructive pulmonary disease with deep learning on raw spirograms identifies new genetic loci and improves risk models[J]. Nat Genet, 2023, 55(5): 787-795.
[7] Martinez FJ, Han MK, Lopez C, et al. Discriminative accuracy of the CAPTURE tool for identifying chronic obstructive pulmonary disease in US primary care settings[J]. JAMA, 2023, 329(6): 490-501.
[8] Siddharthan T, Pollard SL, Quaderi SA, et al. Discriminative accuracy of chronic obstructive pulmonary disease screening instruments in 3 low- and middle-income country settings[J]. JAMA, 2022, 327(2): 151-160.
[9] Huynh C, Whitmore GA, Vandemheen KL, et al. Derivation and validation of the UCAP-Q case-finding questionnaire to detect undiagnosed asthma and COPD[J]. Eur Respir J, 2022, 60(3): 2103243. doi:10.1183/13993003.03243-2021.
[10] Liang ZY, Zhong NS, Chen RC, et al. Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China(COMPASS): study design, protocol and rationale[J]. ERJ Open Res, 2021, 7(3): 00201-02021.
[11] Li Y, Wen FQ, Ma QL, et al. Use of CAPTURE to identify individuals who may or may not require treatment for chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2023, 208(4): 435-441.
[12] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseas(2022 report)[EB/OL].(2021-11-17)[2024-01-30]. https://goldcopd.org/.
[13] Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2018, 197(12): 1540-1551.
[14] Çolak Y, Afzal S, Nordestgaard BG, et al. Prevalence, characteristics, and prognosis of early chronic obstructive pulmonary disease. The Copenhagen general population study[J]. Am J Respir Crit Care Med, 2020, 201(6): 671-680.
[15] Çolak Y, Afzal S, Nordestgaard BG, et al. Importance of early COPD in young adults for development of clinical COPD: findings from the Copenhagen general population study[J]. Am J Respir Crit Care Med, 2021, 203(10): 1245-1256.
[16] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseas(2023 report)[EB/OL].(2022-11-14)[2023-03-30]. https://goldcopd.org/.
[17] Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease[J]. N Engl J Med, 2015, 373(2): 111-122.
[18] Marott JL, Ingebrigtsen TS, Çolak Y, et al. Lung function trajectories leading to chronic obstructive pulmonary disease as predictors of exacerbations and mortality[J]. Am J Respir Crit Care Med, 2020, 202(2): 210-218.
[19] Bui DS, Lodge CJ, Burgess JA, et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life[J]. Lancet Respir Med, 2018, 6(7): 535-544.
[20] Dharmage SC, Bui DS, Walters EH, et al. Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study[J]. Lancet Respir Med, 2023, 11(3): 273-282.
[21] Park J, Hobbs BD, Crapo JD, et al. Subtyping COPD by using visual and quantitative CT imaging features[J]. Chest, 2020, 157(1): 47-60.
[22] Bodduluri S, Kizhakke Puliyakote A, Nakhmani A, et al. Computed tomography-based airway surface area-to-volume ratio for phenotyping airway remodeling in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2021, 203(2): 185-191.
[23] Diaz AA, Orejas JL, Grumley S, et al. Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease[J]. JAMA, 2023, 329(21): 1832-1839.
[24] Pistenmaa CL, Nardelli P, Ash SY, et al. Pulmonary arterial pruning and longitudinal change in percent emphysema and lung function: the genetic epidemiology of COPD study[J]. Chest, 2021, 160(2): 470-480.
[25] Christenson SA, van den Berge M, Faiz A, et al. An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup[J]. J Clin Invest, 2019, 129(1): 169-181.
[26] Zhang JZ, Xu HF, Qiao DD, et al. A polygenic risk score and age of diagnosis of COPD[J]. Eur Respir J, 2022, 60(3): 2101954. doi:10.1183/13993003.01954-2021.
[27] Moll M, Lutz SM, Ghosh AJ, et al. Relative contributions of family history and a polygenic risk score on COPD and related outcomes: COPDGene and ECLIPSE studies[J]. BMJ Open Respir Res, 2020, 7(1): e000755. doi:10.1136/bmjresp-2020-000755.
[28] Moll M, Boueiz A, Ghosh AJ, et al. Development of a blood-based transcriptional risk score for chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2022, 205(2): 161-170. doi:10.1164/rccm.202107-1584OC.
[29] Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis[J]. Am J Respir Crit Care Med, 2021, 203(12): 1488-1502.
[30] Yan ZZ, Chen BX, Yang YQ, et al. Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions[J]. Nat Microbiol, 2022, 7(9): 1361-1375.
[31] Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD[J]. Chest, 2016, 149(5): 1181-1196.
[32] Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis[J]. Thorax, 2016, 71(1): 15-25.
[33] Donohue JF, Jones PW, Bartels C, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2018, 49: 11-19. doi:10.1016/j.pupt.2017.12.005.
[34] Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial[J]. Respir Res, 2019, 20(1): 238. doi:10.1186/s12931-019-1193-9.
[35] Ray R, Tombs L, Naya I, et al. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: a pooled post hoc analysis of seven clinical trials[J]. Pulm Pharmacol Ther, 2019, 57: 101802. doi:10.1016/j.pupt.2019.101802.
[36] Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease(KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial[J]. Lancet Respir Med, 2018, 6(10): 747-758.
[37] Muro S, Sugiura H, Darken P, et al. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts[J]. Respir Res, 2021, 22(1): 187. doi:10.1186/s12931-021-01773-1.
[38] Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD[J]. N Engl J Med, 2020, 383(1): 35-48.
[39] Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study[J]. Am J Respir Crit Care Med, 2021, 203(5): 553-564.
[40] Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD[J]. N Engl J Med, 2018, 378(18): 1671-1680.
[41] Halpin DMG, Dransfield MT, Han MK, et al. The effect of exacerbation history on outcomes in the IMPACT trial[J]. Eur Respir J, 2020, 55(5): 1901921. doi:10.1183/13993003.01921-2019.
[42] Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2020, 201(12): 1508-1516.
[43] Han MK, Criner GJ, Dransfield MT, et al. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial[J]. Am J Respir Crit Care Med, 2020, 202(9): 1237-1243.
[44] Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD[J]. Chest, 2019, 155(4): 758-770.
[45] Suissa S, DellAniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice[J]. Chest, 2020, 157(4): 846-855.
[46] Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial[J]. Lancet Respir Med, 2019, 7(9): 745-756.
[47] Kerkhof M, Voorham J, Dorinsky P, et al. Association between COPD exacerbations and lung function decline during maintenance therapy[J]. Thorax, 2020, 75(9): 744-753.
[48] Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials[J]. Lancet Respir Med, 2018, 6(2): 117-126.
[49] Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A network analysis[J]. Am J Respir Crit Care Med, 2020, 201(9): 1078-1085.
[50] Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2018, 141(6): 2037-2047.e10.
[51] Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations[J]. N Engl J Med, 2019, 381(11): 1023-1034.
[52] Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies[J]. Lancet Respir Med, 2020, 8(2): 158-170.
[53] Le Floch A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation[J]. Allergy, 2020, 75(5): 1188-1204.
[54] Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts[J]. N Engl J Med, 2023, 389(3): 205-214.
[1] ZHANG Kai, SI Shucheng, LI Jiqing, LIU Xiaowen, ZHAO Yingqi, XUE Fuzhong. Mendelian randomization study of sleep phenotypes and irritable bowel syndrome [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 109-114.
[2] ZHOU Na, PAN Yingfang, SHAO Jingru, LI Jing, SONG Yonghong, XU Qun, LYU Hongjuan. Clinical significance of Rh phenotype distribution and irregular antibody screening in RhD negative blood donors in Jinan of Shandong Province [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 98-103.
[3] WANG Bo, XUE Jiang, LIU Aihong, ZHAI Ruirui, WANG Yibiao. Rapamycin improved pulmonary artery hypertension via modulating the phenotypes of macrophages [J]. Journal of Shandong University (Health Sciences), 2018, 56(4): 51-57.
[4] ZHOU Lanlan, PAN Xueyi, GUO Yu. Clinical characteristics and prognosis of 48 patients with mixed phenotype acute leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 79-83.
[5] HUANG Fen， JIANG Yu . Correlation between hypertriglyceridemic-waist phenotype and mild cognitive impairment in patients with IGT [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 72-74.
[6] GUO Xiao-yu1, GAO Yan-qiu1, LIU Zhao-xu2. Application of the UPOINT clinical classification in patients with chronic prostatitis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 62-66.
[7] ZHANG Qian1，2, QIAN Fen-hong3, ZHOU Lin-fu4, WEI Guo-zhen1,BAI Jian-ling5, YIN Kai-sheng4, SHI Yi2. Association of TLR7/8 polymorphisms with risk and severity of asthma in Han population of Jiangsu province of China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(2): 93-98.
[8] QIAO Wenjing1， GUO Nongjian1， DING Botong2， CHEN Yun1， ZHOU Yawei1. Combined measurement of HLA-DRB1*1501 and the TNF-α-308 gene polymorphism in predicting response to immunosuppressive
therapy for aplastic anemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(7): 73-76.
[9] SUN Lei1，WU Jing-jing2，YI Shou-nan2，CHEN Li1. Isolation and amplification of human CD4+CD25+ regulatory T cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(12): 1-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd